A new UK start-up based on technology from King’s College London has received funding from Advent Venture Partners. CoCo Therapeutics Ltd will progress an approach for Alzheimer’s disease that involves the retinoic acid receptor, RAR-alpha. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
